Skip to content
BiologicalX

Comparison

Selank vs Thymosin Alpha-1

Side-by-side of Selank and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Selank

  • Synthetic heptapeptide analog of tuftsin developed in Russia in the 1990s
  • Approved in Russia for generalized anxiety disorder and asthenic conditions
  • Russian RCTs report anxiolytic effects comparable to medazepam without sedation or dependence
  • Modulates GABAergic and serotonergic signaling and BDNF expression in preclinical models
  • Most commonly administered intranasally; subcutaneous use is anecdotal
  • No Western-validated trials; not FDA approved; research-use-only outside Russia

Thymosin Alpha-1

  • 28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
  • Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
  • Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
  • Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
  • Standard label dose: 1.6 mg subcutaneously twice weekly
  • Cleanest safety profile in the peptide class with hundreds of regulated trials behind it

Side-by-side

Attribute Selank Thymosin Alpha-1
Category peptide peptide
Also known as TP-7, Tuftsin analog Talpha1, Ta1, Zadaxin, Thymalfasin
Half-life (hr) 0.5 2
Typical dose (mg) 0.4 1.6
Dosing frequency 2-3x daily (intranasal) 2x weekly
Routes intranasal, subcutaneous subcutaneous, intramuscular
Onset (hr) 0.25 24
Peak (hr) 1 168
Molecular weight 751.85 3108.32
Molecular formula C33H57N11O9 C129H215N33O55
Mechanism Modulates GABAergic, serotonergic, and dopaminergic signaling. Increases BDNF expression in hippocampal neurons in preclinical models. Modulates enkephalin levels and immune cytokine signaling via tuftsin-like activity. Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells.
Legal status Approved as a prescription anxiolytic in Russia; not FDA approved; research-use-only grey market in most other jurisdictions Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List
WADA status unknown unknown
DEA / Rx Not FDA approved; not scheduled; research-chemical status outside Russia Rx only via international approval or US compounding (no controlled-substance schedule)
Pregnancy Not recommended; insufficient data Not recommended; insufficient data
CAS 129954-34-3 62304-98-7
PubChem CID 11765600 16130571
Wikidata Q4416793 Q913854

Safety profile

Selank

Common side effects

  • mild nasal irritation (intranasal)
  • transient drowsiness (uncommon)
  • mild headache

Contraindications

  • pregnancy
  • lactation
  • severe psychiatric disorder (insufficient data)

Interactions

  • benzodiazepines: additive anxiolytic effect; potential for over-sedation when stacked(moderate)
  • SSRIs: no documented adverse interaction; co-administration described in Russian protocols(minor)

Thymosin Alpha-1

Common side effects

  • mild injection-site irritation (rare)
  • transient mild fatigue (rare)
  • occasional headache (rare)

Contraindications

  • pregnancy
  • lactation
  • active organ transplant rejection therapy
  • systemic immunosuppression for autoimmune disease (relative)
  • severe active autoimmune disease (caution)

Interactions

  • interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
  • calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
  • antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
  • vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)

Which Should You Take?

Thymosin Alpha-1 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List, with a Tier-A outcome catalogued. Selank is the right call when one of the conditionals below applies.

  • If your priority is focus or working memory, pick Selank.
  • If your priority is anxiety reduction, pick Selank.
  • If your priority is immune support, pick Thymosin Alpha-1.
  • If your priority is post-training recovery, pick Thymosin Alpha-1.

Edge case: Half-lives differ materially (Selank ~0.5 hr vs Thymosin Alpha-1 ~2 hr). Thymosin Alpha-1 reaches steady state faster; Selank is easier to dial in if tolerability is uncertain.

Default choice: Thymosin Alpha-1. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Selank only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Selank and Thymosin Alpha-1?

Selank and Thymosin Alpha-1 differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Selank or Thymosin Alpha-1?

Selank half-life is 0.5 hours; Thymosin Alpha-1 half-life is 2 hours.

Can you stack Selank with Thymosin Alpha-1?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper